| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial
|
Sandmaier, Brenda M
|
|
|
|
8 |
p. e409-e418
|
artikel
|
| 2 |
Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma
|
Lim, Sean H
|
|
|
|
8 |
p. e542-e544
|
artikel
|
| 3 |
Antithrombotic prophylaxis for symptomatic outpatients with COVID-19: less is consistently more
|
Connors, Jean M
|
|
|
|
8 |
p. e551-e553
|
artikel
|
| 4 |
Biosimilars: an optimistic outlook, but vigilance is needed
|
The Lancet Haematology,
|
|
2017
|
|
8 |
p. e341-
1 p.
|
artikel
|
| 5 |
Bleeding disorders: making strides towards treatment for all
|
The Lancet Haematology,
|
|
|
|
8 |
p. e551
|
artikel
|
| 6 |
Blunted humoral response after mRNA vaccine in patients with haematological malignancies
|
Kamboj, Mini
|
|
|
|
8 |
p. e540-e542
|
artikel
|
| 7 |
Brentuximab vedotin with AVD for stage II–IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial
|
Rubinstein, Paul G
|
|
|
|
8 |
p. e624-e632
|
artikel
|
| 8 |
Cardiovascular adverse events following treatment for non-Hodgkin lymphoma
|
Jayaraj, Rama
|
|
|
|
8 |
p. e557
|
artikel
|
| 9 |
Cardiovascular adverse events following treatment for non-Hodgkin lymphoma – Authors' reply
|
Linschoten, Marijke
|
|
|
|
8 |
p. e557-e558
|
artikel
|
| 10 |
Cecilia Guillermo—leading Uruguay's battle against haematological diseases
|
Kirby, Tony
|
|
|
|
8 |
p. e559
|
artikel
|
| 11 |
Choosing the ideal immunotherapy for high-risk ALL
|
|
|
|
|
8 |
p. e560-e561
|
artikel
|
| 12 |
Combination therapy for relapsed peripheral T-cell lymphoma: is two better than one?
|
Bachy, Emmanuel
|
|
2015
|
|
8 |
p. e307-e308
nvt p.
|
artikel
|
| 13 |
Correction to Lancet Haematol 2016; 3: e323
|
|
|
2016
|
|
8 |
p. e361-
1 p.
|
artikel
|
| 14 |
Correction to Lancet Haematol 2017; 4: e431–42
|
|
|
2018
|
|
8 |
p. e332
|
artikel
|
| 15 |
Correction to Lancet Haematol 2018; 5: e289–98
|
|
|
2018
|
|
8 |
p. e332
|
artikel
|
| 16 |
Correction to Lancet Haematol 2018; 5: e273–74
|
|
|
2018
|
|
8 |
p. e332
|
artikel
|
| 17 |
Correction to Lancet Haematol 2020; 7: e534–40
|
|
|
|
|
8 |
p. e560
|
artikel
|
| 18 |
Correction to Lancet Haematol 2023; 10: e492–94
|
|
|
|
|
8 |
p. e574
|
artikel
|
| 19 |
Correction to Lancet Haematol 2023; 10: e585–99
|
|
|
|
|
8 |
p. e574
|
artikel
|
| 20 |
Costs of haematological disease high and rising
|
Green, Tony
|
|
2016
|
|
8 |
p. e353-e354
nvt p.
|
artikel
|
| 21 |
COVID-19 vaccination antibody responses in patients with aplastic anaemia and paroxysmal nocturnal haemoglobinuria
|
Pike, Alexandra
|
|
|
|
8 |
p. e553-e556
|
artikel
|
| 22 |
Defining global strategies to improve outcomes in sickle cell disease: a Lancet Haematology Commission
|
Piel, Frédéric B
|
|
|
|
8 |
p. e633-e686
|
artikel
|
| 23 |
Direct oral anticoagulants and cancer: no swansong yet for the low-molecular-weight heparins
|
Noble, Simon I R
|
|
2016
|
|
8 |
p. e357-e358
nvt p.
|
artikel
|
| 24 |
Doping and athlete health
|
The Lancet Haematology,
|
|
2016
|
|
8 |
p. e352-
1 p.
|
artikel
|
| 25 |
Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study
|
Lynch, Ryan C
|
|
|
|
8 |
p. e562-e571
|
artikel
|
| 26 |
Do we perform better when we increase red blood cells?
|
Perrey, Stephane
|
|
2017
|
|
8 |
p. e344-e345
nvt p.
|
artikel
|
| 27 |
Early fibrinogen-concentrate administration in management of trauma-induced coagulopathy
|
David, Jean-Stéphane
|
|
2017
|
|
8 |
p. e348-
1 p.
|
artikel
|
| 28 |
Early fibrinogen-concentrate administration in management of trauma-induced coagulopathy – Authors' reply
|
Innerhofer, Petra
|
|
2017
|
|
8 |
p. e348-e349
nvt p.
|
artikel
|
| 29 |
Economic burden of malignant blood disorders across Europe: a population-based cost analysis
|
Burns, Richeal
|
|
2016
|
|
8 |
p. e362-e370
nvt p.
|
artikel
|
| 30 |
Economic burden of non-malignant blood disorders across Europe: a population-based cost study
|
Luengo-Fernandez, Ramon
|
|
2016
|
|
8 |
p. e371-e378
nvt p.
|
artikel
|
| 31 |
Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial
|
Raskob, Gary E
|
|
2016
|
|
8 |
p. e379-e387
nvt p.
|
artikel
|
| 32 |
Effects of erythropoietin on cycling performance of well trained cyclists: a double-blind, randomised, placebo-controlled trial
|
Heuberger, Jules A A C
|
|
2017
|
|
8 |
p. e374-e386
nvt p.
|
artikel
|
| 33 |
Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial
|
Kim, Won Seog
|
|
2017
|
|
8 |
p. e362-e373
nvt p.
|
artikel
|
| 34 |
EHA 2021 Virtual Congress
|
Stretton, Owen
|
|
|
|
8 |
p. e546-e547
|
artikel
|
| 35 |
Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study
|
Bussel, James B
|
|
2015
|
|
8 |
p. e315-e325
nvt p.
|
artikel
|
| 36 |
Empowering children and adolescents with sickle cell disease: a transition journey to adult care
|
Badawy, Sherif M
|
|
|
|
8 |
p. e562
|
artikel
|
| 37 |
Ending the burden of sickle cell disease in Africa
|
Moeti, Matshidiso R
|
|
|
|
8 |
p. e567-e569
|
artikel
|
| 38 |
Endothelial cells orchestrate COVID-19 coagulopathy
|
O'Sullivan, Jamie M
|
|
|
|
8 |
p. e553-e555
|
artikel
|
| 39 |
Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study
|
Goshua, George
|
|
|
|
8 |
p. e575-e582
|
artikel
|
| 40 |
Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial
|
Barco, Stefano
|
|
|
|
8 |
p. e585-e593
|
artikel
|
| 41 |
Equal opportunities for clinical trial participation
|
The Lancet Haematology,
|
|
|
|
8 |
p. e535
|
artikel
|
| 42 |
European Hematology Association Hybrid Congress 2022
|
Stretton, Owen
|
|
|
|
8 |
p. e557-e558
|
artikel
|
| 43 |
European Hematology Association 2023 Hybrid Congress
|
del Pozo Martín, Yaiza
|
|
|
|
8 |
p. e575-e576
|
artikel
|
| 44 |
[18F]FDG-PET-CT compared with CT for persistent or recurrent neutropenic fever in high-risk patients (PIPPIN): a multicentre, open-label, phase 3, randomised, controlled trial
|
Douglas, Abby
|
|
|
|
8 |
p. e573-e584
|
artikel
|
| 45 |
[18F]FDG-PET-CT in neutropenic fever: a picture searching for a frame(work)
|
Stephens, R Scott
|
|
|
|
8 |
p. e549-e551
|
artikel
|
| 46 |
Finding ferritin in the plateaus and valleys of iron deficiency
|
Braat, Sabine
|
|
|
|
8 |
p. e539-e540
|
artikel
|
| 47 |
Following-up allogeneic transplantation recipients during the COVID-19 pandemic
|
Lupo-Stanghellini, Maria Teresa
|
|
|
|
8 |
p. e564-e565
|
artikel
|
| 48 |
Genes expressed in red cells could shape a malaria attack
|
Luzzatto, Lucio
|
|
2018
|
|
8 |
p. e322-e323
|
artikel
|
| 49 |
Genes in the blood
|
Davis, Sophia
|
|
|
|
8 |
p. e550
|
artikel
|
| 50 |
Global advocacy from Zambia for the hopes and dreams of people with sickle cell disease
|
Kasongo, Lwimba
|
|
|
|
8 |
p. e583-e584
|
artikel
|
| 51 |
Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000–2021: a systematic analysis from the Global Burden of Disease Study 2021
|
|
|
|
|
8 |
p. e585-e599
|
artikel
|
| 52 |
Health-care use drives the economic burden of blood disorders in Europe
|
Pauwels, Kim
|
|
2016
|
|
8 |
p. e355-e356
nvt p.
|
artikel
|
| 53 |
Heavy menstrual blood loss in patients with von Willebrand disease: an unsolved problem
|
Leebeek, Frank W G
|
|
|
|
8 |
p. e561-e562
|
artikel
|
| 54 |
Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study
|
Kantarjian, Hagop M
|
|
2017
|
|
8 |
p. e387-e398
nvt p.
|
artikel
|
| 55 |
High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial
|
Illerhaus, Gerald
|
|
2016
|
|
8 |
p. e388-e397
nvt p.
|
artikel
|
| 56 |
High-dose therapy for primary CNS lymphoma
|
Hohaus, Stefan
|
|
2016
|
|
8 |
p. e359-e360
nvt p.
|
artikel
|
| 57 |
HIV-associated Burkitt lymphoma
|
Atallah-Yunes, Suheil Albert
|
|
|
|
8 |
p. e594-e600
|
artikel
|
| 58 |
Human candidate gene polymorphisms and risk of severe malaria in children in Kilifi, Kenya: a case-control association study
|
Ndila, Carolyne M
|
|
2018
|
|
8 |
p. e333-e345
|
artikel
|
| 59 |
Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial
|
Davids, Matthew S
|
|
|
|
8 |
p. e419-e428
|
artikel
|
| 60 |
Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study
|
Maneikis, Kazimieras
|
|
|
|
8 |
p. e583-e592
|
artikel
|
| 61 |
Improving the investigative approach to polycythaemia vera: a critical assessment of current evidence and vision for the future
|
Ronner, Lukas
|
|
|
|
8 |
p. e605-e612
|
artikel
|
| 62 |
International Society on Thrombosis and Haemostasis Congress 2023
|
Cookson, Emma
|
|
|
|
8 |
p. e577-e578
|
artikel
|
| 63 |
ISTH 2015 Congress
|
Smith, Lan-Lan
|
|
2015
|
|
8 |
p. e313-e314
nvt p.
|
artikel
|
| 64 |
Is venetoclax the new backbone of acute myeloid leukaemia therapy?
|
Jain, Prachi
|
|
|
|
8 |
p. e536-e537
|
artikel
|
| 65 |
Is venous thromboembolism a preventable cause of death?
|
Schulman, Sam
|
|
|
|
8 |
p. e555-e556
|
artikel
|
| 66 |
Leukaemia and myeloid malignancy among people exposed to low doses (<100 mSv) of ionising radiation during childhood: a pooled analysis of nine historical cohort studies
|
Little, Mark P
|
|
2018
|
|
8 |
p. e346-e358
|
artikel
|
| 67 |
Leukaemia risk associated with low-dose radiation
|
Hourigan, Christopher S
|
|
2018
|
|
8 |
p. e324-e325
|
artikel
|
| 68 |
Lymphoma: that's classified
|
The Lancet Haematology,
|
|
2015
|
|
8 |
p. e306-
1 p.
|
artikel
|
| 69 |
Management of anticoagulant-refractory thrombotic antiphospholipid syndrome
|
Cohen, Hannah
|
|
|
|
8 |
p. e613-e623
|
artikel
|
| 70 |
Mental health and psychological resilience in sickle cell disease
|
Treadwell, Marsha J
|
|
|
|
8 |
p. e569-e571
|
artikel
|
| 71 |
Mortality risk associated with venous thromboembolism: a systematic review and Bayesian meta-analysis
|
Klemen, Nicholas D
|
|
|
|
8 |
p. e583-e593
|
artikel
|
| 72 |
Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study
|
Morschhauser, Franck
|
|
|
|
8 |
p. e429-e437
|
artikel
|
| 73 |
Optimising maintenance therapy after transplantation: sorafenib's role in patients with FLT3-ITD acute myeloid leukaemia
|
Yilmaz, Musa
|
|
|
|
8 |
p. e559-e561
|
artikel
|
| 74 |
Optimising treatment of HIV-associated Hodgkin lymphoma
|
Hoffmann, Christian
|
|
|
|
8 |
p. e563-e564
|
artikel
|
| 75 |
Packed red blood cell transfusion in preterm infants
|
Bellach, Luise
|
|
|
|
8 |
p. e615-e626
|
artikel
|
| 76 |
Palliation for haematological and solid tumours: what difference?
|
Noble, Simon
|
|
2015
|
|
8 |
p. e309-e310
nvt p.
|
artikel
|
| 77 |
Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial
|
Tan, Daryl
|
|
2015
|
|
8 |
p. e326-e333
nvt p.
|
artikel
|
| 78 |
Physiologically based serum ferritin thresholds for iron deficiency in children and non-pregnant women: a US National Health and Nutrition Examination Surveys (NHANES) serial cross-sectional study
|
Mei, Zuguo
|
|
|
|
8 |
p. e572-e582
|
artikel
|
| 79 |
Progressive multifocal leukoencephalopathy in patients treated with rituximab: a 20-year review from the Southern Network on Adverse Reactions
|
Bennett, Charles L
|
|
|
|
8 |
p. e593-e604
|
artikel
|
| 80 |
Public health and programme development in sickle cell disease in Ghana: the legacy of Kwaku Ohene-Frempong
|
Odame, Isaac
|
|
|
|
8 |
p. e579-e580
|
artikel
|
| 81 |
23rd European Hematology Association Congress
|
Smith, Lan-Lan
|
|
2018
|
|
8 |
p. e330-e331
|
artikel
|
| 82 |
Recombinant von Willebrand factor and tranexamic acid for heavy menstrual bleeding in patients with mild and moderate von Willebrand disease in the USA (VWDMin): a phase 3, open-label, randomised, crossover trial
|
Ragni, Margaret V
|
|
|
|
8 |
p. e612-e623
|
artikel
|
| 83 |
Refining chemotherapy for chronic lymphocytic leukaemia with targeted drugs
|
Wendtner, Clemens-Martin
|
|
|
|
8 |
p. e389-e390
|
artikel
|
| 84 |
Risk of second primary cancer following myeloid neoplasia and risk of myeloid neoplasia as second primary cancer: a nationwide, observational follow up study in Sweden
|
Chattopadhyay, Subhayan
|
|
2018
|
|
8 |
p. e368-e377
|
artikel
|
| 85 |
Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis
|
Federico, Massimo
|
|
2018
|
|
8 |
p. e359-e367
|
artikel
|
| 86 |
Rituximab as a first step in tackling transformation
|
Okosun, Jessica
|
|
2018
|
|
8 |
p. e326-e327
|
artikel
|
| 87 |
Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study
|
Jurczak, Wojciech
|
|
2017
|
|
8 |
p. e350-e361
nvt p.
|
artikel
|
| 88 |
Rituximab biosimilars for B-cell lymphomas: a decade of real-world experience from India
|
Nair, Reena
|
|
|
|
8 |
p. e548-e549
|
artikel
|
| 89 |
Rituximab biosimilars: introduction into clinical practice
|
Makita, Shinichi
|
|
2017
|
|
8 |
p. e342-e343
nvt p.
|
artikel
|
| 90 |
Rosline Hassan: building the future of haemato-pathology in Malaysia
|
Burki, Talha K
|
|
|
|
8 |
p. e551
|
artikel
|
| 91 |
Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial
|
Taylor, Justin
|
|
|
|
8 |
p. e566-e574
|
artikel
|
| 92 |
Secondary primary cancers before and after myeloid neoplasia: a two-way street
|
Garcia-Manero, Guillermo
|
|
2018
|
|
8 |
p. e328-e329
|
artikel
|
| 93 |
Selective liver toxicity and therapeutic progress in acute lymphoblastic leukaemia
|
Bassan, Renato
|
|
2017
|
|
8 |
p. e346-e347
nvt p.
|
artikel
|
| 94 |
Sequencing therapies in Hodgkin lymphoma
|
Phillips, Elizabeth H
|
|
|
|
8 |
p. e537-e539
|
artikel
|
| 95 |
Short versus extended treatment with a carbapenem in patients with high-risk fever of unknown origin during neutropenia: a non-inferiority, open-label, multicentre, randomised trial
|
de Jonge, Nick A
|
|
|
|
8 |
p. e563-e572
|
artikel
|
| 96 |
Sickle cell disease: a new era
|
Simpson, Shmona
|
|
|
|
8 |
p. e393-e394
|
artikel
|
| 97 |
Sickle cell disease in the Caribbean: progress in newborn screening, clinical care, and research through collaboration
|
Knight-Madden, Jennifer
|
|
|
|
8 |
p. e581-e582
|
artikel
|
| 98 |
Sickle cell disease landscape and challenges in the EU: the ERN-EuroBloodNet perspective
|
Mañú Pereira, María del Mar
|
|
|
|
8 |
p. e687-e694
|
artikel
|
| 99 |
Sickle cell disease: time to act on the most neglected global health problem
|
Osei, Miriam A
|
|
|
|
8 |
p. e558-e559
|
artikel
|
| 100 |
Sickle cell disease—unity and patient-centred education
|
The Lancet Haematology,
|
|
|
|
8 |
p. e557
|
artikel
|
| 101 |
Sirolimus-based graft-versus-host disease prophylaxis
|
Ruggeri, Annalisa
|
|
|
|
8 |
p. e387-e388
|
artikel
|
| 102 |
Social determinants of health: the next frontier for improving care and outcomes in sickle cell disease
|
Porter, Jerlym S
|
|
|
|
8 |
p. e571-e573
|
artikel
|
| 103 |
Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial
|
Xuan, Li
|
|
|
|
8 |
p. e600-e611
|
artikel
|
| 104 |
Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts
|
Zeidan, Amer M
|
|
|
|
8 |
p. e601-e612
|
artikel
|
| 105 |
Subcutaneous versus intravenous daratumumab in multiple myeloma
|
Shibusawa, Motoharu
|
|
|
|
8 |
p. e558
|
artikel
|
| 106 |
Subcutaneous versus intravenous daratumumab in multiple myeloma – Authors' reply
|
Mateos, Maria-Victoria
|
|
|
|
8 |
p. e559
|
artikel
|
| 107 |
Sudden severe thrombocytopenia in a patient in the recovery stage of COVID-19
|
Chen, Wanxin
|
|
|
|
8 |
p. e624
|
artikel
|
| 108 |
Suitability of haematopoietic cell donors: updated consensus recommendations from the WBMT standing committee on donor issues
|
Worel, Nina
|
|
|
|
8 |
p. e605-e614
|
artikel
|
| 109 |
Symptom burden of haematological malignancies as death approaches in a community palliative care service: a retrospective cohort study of a consecutive case series
|
LeBlanc, Thomas W
|
|
2015
|
|
8 |
p. e334-e338
nvt p.
|
artikel
|
| 110 |
Tailoring care for patients with haematological malignancies
|
Guan, Jennifer Huey Chen
|
|
|
|
8 |
p. e559
|
artikel
|
| 111 |
Targeting Hedgehog in haematological malignancies
|
Ghia, Paolo
|
|
2015
|
|
8 |
p. e311-e312
nvt p.
|
artikel
|
| 112 |
The FDA's definitions, designations, and drug approvals: too daring?
|
The Lancet Haematology,
|
|
2018
|
|
8 |
p. e321
|
artikel
|
| 113 |
The Lancet Haematology Commission on sickle cell disease: key recommendations
|
|
|
|
|
8 |
p. e564-e567
|
artikel
|
| 114 |
The long and short of antibiotic management for neutropenic fever in patients with haematological malignancy
|
Teh, Benjamin W
|
|
|
|
8 |
p. e548-e549
|
artikel
|
| 115 |
The true value of second-generation TKIs as first-line therapy in chronic myeloid leukaemia
|
Andrews, Claire N
|
|
|
|
8 |
p. e385-e386
|
artikel
|
| 116 |
25th European Hematology Association Annual Congress
|
Cookson, Emma
|
|
|
|
8 |
p. e561-e562
|
artikel
|
| 117 |
24th European Hematology Association Congress
|
Smith, Lan-Lan
|
|
|
|
8 |
p. e396-e397
|
artikel
|
| 118 |
The value of affordable care
|
The Lancet Haematology,
|
|
|
|
8 |
p. e384
|
artikel
|
| 119 |
Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial
|
Cools, Frank
|
|
|
|
8 |
p. e594-e604
|
artikel
|
| 120 |
Thrombosis and mental health
|
The Lancet Haematology,
|
|
|
|
8 |
p. e547
|
artikel
|
| 121 |
Treating myelodysplastic syndromes by nuclear transport inhibition
|
Sockel, Katja
|
|
|
|
8 |
p. e552-e553
|
artikel
|
| 122 |
Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study
|
Shih, Ya-Chen Tina
|
|
|
|
8 |
p. e398-e408
|
artikel
|
| 123 |
Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study
|
Martinelli, Giovanni
|
|
2015
|
|
8 |
p. e339-e346
nvt p.
|
artikel
|
| 124 |
UK changes LGBT+ blood donation rules but Africa restriction remains
|
Makoni, Munyaradzi
|
|
|
|
8 |
p. e545
|
artikel
|
| 125 |
Vania Hungria—treating myeloma with restricted resources
|
Kirby, Tony
|
|
|
|
8 |
p. e563
|
artikel
|
| 126 |
Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial
|
Kadia, Tapan M
|
|
|
|
8 |
p. e552-e561
|
artikel
|
| 127 |
War in the Blood: experiencing CAR-T cell therapy
|
Burki, Talha K
|
|
|
|
8 |
p. e395
|
artikel
|
| 128 |
Will GALEN become more RELEVANT?
|
von Keudell, Gottfried
|
|
|
|
8 |
p. e391-e392
|
artikel
|
Tijdschrift beschrijving